The objective of this study was to evaluate the effect of including bone in DIXON-based attenuation correction for 18 F-fluciclovine Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI) of primary and recurrent prostate cancer.
The objective of this study was to evaluate the effect of including bone in DIXON-based attenuation correction for 18 F-fluciclovine Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI) of primary and recurrent prostate cancer.
Methods:
18 F-fluciclovine PET data from two PET/MRI studies -one for staging of highrisk prostate cancer (28 patients) and one for diagnosis of recurrent prostate cancer (81 patients) -were reconstructed with a 4-compartment (reference) and 5-compartment attenuation map. In the latter, continuous linear attenuation coefficients for bone were included by co-registration with an atlas. The maximum and mean 50%
isocontour standardized uptake values (SUV max and SUV iso , respectively) of primary, locally recurrent, and metastatic lesions were compared between the two reconstruction methods using linear mixed-effects models. In addition, mean SUVs were obtained from bone marrow in the third lumbar vertebra (L3) to investigate the effect of including bone attenuation on lesion-to-bone marrow SUV ratios (SUVRmax and SUVRiso; recurrence study only). The 5-compartment attenuation maps were visually compared to the in-phase DIXON MR images for evaluation of bone registration errors near the lesions. P-values < 0.05 were considered significant. Results: Sixty-two (62) lesions from 39 patients were evaluated. Bone registration errors were found near 19 (31%) of these lesions. In the remaining 8 primary prostate tumors, 7 locally recurrent lesions, and 28 lymph node metastases without bone registration errors, using the 5-compartment attenuation map was associated with small but significant increases in SUVmax [2.5%; 95% confidence interval (CI) 2.0%-3.0%; p<0.001] and SUViso (2.5%; 95% CI 1.9%-3.0%; p<0.001), but not SUVRmax (0.2%; 95% CI -0.5%-0.9%; p=0.604) and SUVRiso (0.2%; 95% CI -0.6%-1.0%; p=0.581), in comparison to the 4-compartment attenuation map. Conclusion: The investigated method for atlas-based inclusion of bone in 18 F-fluciclovine PET/MRI attenuation correction has only a small effect on the SUVs of soft-tissue prostate cancer lesions, and no effect on their lesion-to-bone marrow SUVRs when using signal from L3 as a reference. The attenuation maps should always be checked for registration artefacts for lesions in or close to the bones.
INTRODUCTION
Medical imaging plays an increasingly important role in the management of prostate cancer, which is the most frequently detected type of cancer in men in developed countries (1) . Multiparametric Magnetic Resonance Imaging (MRI), i.e. the combination of anatomical T2-weighted imaging and functional diffusion-weighted and dynamic contrast-enhanced imaging, is currently recommended for staging of primary prostate cancer (2), while molecular imaging with Positron Emission Tomography (PET) has
shown promise for the detection of primary and recurrent prostate cancer (3) (4) (5) (6) (7) . Since the introduction of integrated PET/MRI scanners, these complementary data sets can be simultaneously acquired, thereby potentially improving the diagnostic accuracy in comparison to either modality alone (3, 4, 8, 9) .
In contrast to computed tomography (CT), however, MRI does not provide an estimate of the electron densities that determine the attenuation of the 511 keV annihilation photons in the patient's body. Correction for attenuation, which is required for quantitatively accurate PET imaging, is therefore technically challenging on a PET/MRI system. In current clinical practice, fast T1-weighted or DIXON MR scans are used to create an attenuation map with fixed linear attenuation coefficients for three (soft tissue, lung, background air) (10) or four segmented compartments (soft tissue, fat, lung, and background air) (11), respectively. In both cases, the linear attenuation coefficient of soft tissue is assigned to bones, which typically leads to an underestimation of the standardized uptake values (SUVs) in lesions in and close to bony structures (12, 13) . In a simulation study with known ground truth, Keeremans et al estimated the underestimation of SUVs in the prostate region to be around -4% (13).
Paulus et al recently presented a method to solve this issue, by including continuous bone linear attenuation coefficients in the DIXON-based attenuation map, based on co-registration of the DIXON images with an atlas of MR and CT pairs of the major bones in the body (14) . This method, which is currently implemented on Siemens mMR PET/MRI scanners, was reported to substantially reduce the underestimation of SUV in bone lesions (14, 15) and soft tissue lesions in the brain (16) . The effect on the SUV in soft-tissue lesions in the body, on the other hand, was particularly small (14, 15 
MATERIALS AND METHODS

Patients
In this work, we retrospectively reconstructed and analyzed 
Imaging and Reconstruction
Both imaging studies were performed on a 3 T Biograph mMR PET/MRI scanner (Siemens Healthcare GmbH, Erlangen, Germany). All PET images were offline in the body, as described in more detail by Paulus et al (14) .
In the staging study, the PET images for evaluation of lymph node metastases covered the lymph nodes from the pelvic floor up to the ureteral crossing of the common iliac vessels, as previously described (8, 19) , and were reconstructed from the counts in a time-window 5 -10 minutes post tracer injection. The PET images for evaluation of prostate tumors were centered on the prostate and were reconstructed from the counts in a time-window 33 -38 minutes post tracer-injection. In the recurrence study, PET images were acquired in four consecutive, partly overlapping, 
Volumes-of-interest
For the patients in the staging study, volumes-of-interest (VOIs) of primary prostate tumors and pelvic lymph node metastases were considered. The prostate tumor VOIs were defined as the 50% isocontour of the maximum SUV in the corresponding histology-based VOIs, which were available from a previous study (19) .
The lymph nodes classified as malignant by a nuclear medicine physician were retrospectively identified on the PET images reconstructed with the 4-compartment attenuation map. VOIs were defined as the 50% isocontour of the maximum SUV in a sphere encompassing the entire lymph node. The latter approach was also used to define the VOIs of recurrent prostate tumors, pelvic lymph nodes, para-aortic lymph nodes, and bone lesions in the recurrence study. In all cases, isocontouring was performed separately on the PET images reconstructed with the 4 and 5-compartment attenuation maps. In addition, spherical VOIs (8 mm radius) were placed in the third lumbar vertebra (L3) of the patients in the recurrence study to calculate lesion-to-bone marrow SUVRs.
The maximum and mean SUV (SUVmax and SUViso, respectively) were obtained for each of the lesion VOIs. For the patients in the recurrence study, the mean SUVs of Since a substantial amount of bone registration errors were found near primary prostate tumors (see results), we specifically evaluated the bias in ΔSUV in these regions; for each patient with bone registration errors near a primary tumor, 2 spherical
VOIs of the same size were placed in prostate areas with and without mis-registered bone, respectively. The mean SUV was obtained for both VOIs and ΔSUVs were calculated as described above.
The initial VOIs (before iso-contouring) were delineated using OsiriX (20) (primary tumor VOIs) or ITK-SNAP (21) (all other VOIs). Subsequent iso-contouring, SUV analysis, and calculation of distance to the nearest bone was performed in MATLAB 9.2 (The MathWorks Inc., Natick, MA).
Statistical Analysis
For the lesions without bone registration errors, linear mixed effects models were used to test if ΔSUV and ΔSUVR were different than zero, and to assess if ΔSUV and ΔSUVR were associated with the lesion's distance to the nearest bone.
Furthermore, linear mixed effects models were used to test if ΔSUV was different between lesions with and without bone registration errors. In all cases, patient number was used as a random effect on the intercept to account for multiple lesions per patient. The Wilcoxon signed-rank test was used to test if ΔSUV was different between prostate areas with and without mis-registered bone. P-values < 0.05 were considered significant. MATLAB 9.2 was used for statistical analysis. The largest increase in SUV was found for the bone lesion (ΔSUVmax = 9.0%; ΔSUViso = 8.8%), despite sub-optimal co-registration of the bone atlas (Fig. 1D ). In patients with bone registration errors near primary tumors, ΔSUV was significantly higher in prostate regions with than without mis-registered bone (p < 0.001). The median (range) bias in prostate regions with bone registration errors was +9.6 (4.4 -20.2) percentage point.
RESULTS
For the 43 lesions without artefacts, inclusion of bone in the attenuation map was associated with small but significant overall increases in SUVmax and SUViso [ΔSUVmax = 2.5%, 95% confidence interval (CI) 2.0%-3.0%, p<0.001; SUViso = 2.5%, 95% CI 1.9%-3.0%, p<0.001]. Figure 2A shows that the effect was similar for the prostate (bed) lesions (n = 15; ΔSUV max = 2.2%, 95% CI 1.6%-2.9%, p<0.001; ΔSUV iso = 2.4%, 95% CI 1.4%-3.3%, p<0.001) and the lymph nodes lesions (n = 28; ΔSUVmax = 2.6%, 95% CI 1.9%-3.3%, p<0.001; ΔSUV iso = 2.5%, 95% CI 1.8%-3.2%, p<0.001). Neither ΔSUV max (p = 0.964)
nor ΔSUViso (p = 0.620) was associated with the lesion's distance to the nearest bone (Fig. 3A) .
The inclusion of bone in the attenuation map was not associated with significant changes in SUVRmax or SUVRiso when all lesions of the recurrence study were considered (ΔSUVRmax = 0.2%, 95% CI -0.5%-0.9%, p=0.604; ΔSUVRiso = 0.2%, 95% CI -0.6%-1.0%, p=0.581). Again, the results were comparable between prostate (bed) lesions (ΔSUVRmax = 0.4%, 95% CI -1.4%-2.1%, p=0.676; ΔSUVRiso = 0.8%, 95% CI -1.8%-3.3%, p=0.562) and lymph node lesions (ΔSUVRmax = 0.1%, 95% CI -0.7%-1.0%, p=0.737; ΔSUVRiso = 0.1%, 95% CI -0.7%-0.9%, p=0.581) (Fig. 2B ) and no significant associations were found between with ΔSUVRmax (p = 0.982) or ΔSUVRiso (p = 0.797) and distance to bone (Fig. 3B) .
DISCUSSION
Promising results from several studies with different radiopharmaceuticals indicate that PET/MRI has the potential to play an important role in staging of primary prostate cancer, e.g. (4, 18, 22, 23) , and detection of disease recurrence after initial treatment with curative intent, e.g. (24) (25) (26) (27) . However, in current clinical practice, the high linear attenuation coefficients of the bones in the pelvis and lower abdomen are assumed to be equal to those of soft tissue, which is incorrect. In this study, we applied a commercially available atlas-based method for including bone in the attenuation maps and evaluated its effect on the SUVs and SUVRs of primary and recurrent prostate cancer lesions. We found that including bone resulted in significant but small increases in the SUV of prostate (bed) and lymph node lesions, which were in the order of 2 to 3%. These results agree well previously reported observed and simulated bias values from ignoring bone attenuation (11, (13) (14) (15) . We did not observe an effect of including bone attenuation on lesion-to-bone marrow SUVRs, as the increases in SUV were similar for the lesion and bone marrow. Based on these results, and the bone registration errors discussed below, we deem the inclusion of bone in the PET/MRI attenuation maps not recommendable for the evaluation of soft tissue prostate cancer lesions.
We found that bone registration errors may pose a problem in some patients, PET radiopharmaceuticals, including prostate specific membrane antigen (PSMA) and choline-based tracers, remains to be seen and will be part of future research. In all cases, the atlas-based method may be important for the quantification of uptake in bone lesions, but the attenuation maps should always be checked for bone registration errors.
CONCLUSION
The investigated method for atlas-based inclusion of bone in DIXON-based attenuation correction of 18 F-fluciclovine PET/MRI has only a small effect on the SUVs of soft-tissue prostate cancer lesions, and no effect on their lesion-to-bone marrow SUVRs when using signal from L3 as a reference. The attenuation maps should always be checked for bone registration errors when evaluating lesions in or close to the bones. 
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